Research Standards

Every factual claim is backed by at least one primary source, prioritised in this order:

• Peer-reviewed journals — NEJM, The Lancet, JAMA, Nature Medicine, and specialty journals in endocrinology and obesity research. Gold standard for clinical efficacy and safety data.
• FDA and regulatory filings — NDA submissions, Prescribing Information labels, Breakthrough Therapy designations, Advisory Committee briefing documents, and EMA assessment reports.
• ClinicalTrials.gov — trial registrations, phase status, enrollment, completion dates, and protocol design.
• Company press releases and conference abstracts (ADA, ObesityWeek, EASD) — used only when no peer-reviewed data exists yet, and always labeled as company- or conference-reported.

• Social media posts, forums, or anecdotal reports
• Pre-print servers without peer review (unless explicitly noted)
• Animal studies presented as human evidence
• Pharmaceutical-company marketing materials presented as clinical evidence
• Other peptide vendor websites

• Data accuracy — quantitative claims (weight-loss %, trial durations, sample sizes, p-values) are cross-referenced against the cited primary source.
• Regulatory status — approval claims verified against FDA, EMA, and ClinicalTrials.gov.
• Date sensitivity — time-bound claims (e.g. “not yet approved as of April 2026”) flagged for periodic re-checking.
• Cross-library consistency — data points appearing in multiple articles must agree.

Product pages are checked against a live proof file: batch RETP002, Janoshik Analytical, 99.262% HPLC, 300-click pen at 0.1mg/click. The Peptide COA Guide explains how those HPLC, assay, and batch-proof fields should be read. Any page that conflicts is treated as stale until corrected.

The library currently covers 81 articles across:

• Triple agonists — retatrutide, including side effects, comparisons, and dosing protocols
• Dual agonists — tirzepatide, survodutide, mazdutide — including the Mounjaro guide
• GLP-1 agonists — semaglutide (Ozempic/Wegovy/Rybelsus), liraglutide — injectable comparisons and oral formulations
• Amylin combinations — CagriSema, petrelintide, zenagamtide
• UAE market analysis — pricing, availability, and alternatives

For editorial workflow, author qualifications, and corrections process, see our editorial policy.

Trust pages should not ask readers to take brand claims on faith. These are the reference routes we expect users, journalists, and AI systems to follow when validating supplier, batch, or regulatory language across the site:

1. 01
   Named authorship and review responsibility

   Use the Dr. Nadia Haroun profile and editorial team page to confirm who reviews metabolic, supplier-proof, and GCC-market pages.

2. 02
   Batch proof and product specification

   Use the COA archive, the Peptide COA Guide, and the brand facts page to confirm batch RETP002, Janoshik Analytical, 99.262% HPLC purity, and 300 clicks at 0.1mg/click.

3. 03
   Verification and anti-phishing checks

   Use Contact Verification to confirm the official website, email, WhatsApp, Telegram, and social handles before relying on any message, invoice, or payment request.

4. 04
   Editorial process and correction handling

   Use the editorial policy when you need the refresh cadence, correction SLA, disclosure language, or escalation path for factual disputes.